AMANDA BARFIELD: Open Payments
NPI 1902257009 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$639 in 30 payments from 10 companies in 2025. Trend: 2023 $527 · 2024 $429 · 2025 $639
Food & beverage: $639
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 6 | $175 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $148 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| E.R. Squibb & Sons, L.L.C. | 3 | $54 |
| Neurocrine BioSciences, Inc. | 2 | $51 |
| ABBVIE INC. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Novo Nordisk Inc | 1 | $17 |
| Exact Sciences Corporation | 1 | $15 |
Products named: FANAPT, CAPLYTA, Auvelity, COBENFY, INGREZZA, REXULTI, ABILIFY ASIMTUFII, VRAYLAR.
Industry payments across LA — which companies pay providers there.
